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Abstract Pancreatic L-cell function is essential for the regula-
tion of glucose homeostasis and its impairment leads to diabetes
mellitus. Besides glucose, the major nutrient factor, inputs from
neural and humoral components and intraislet cell^cell commu-
nication act together to guarantee an appropriate pancreatic
L-cell function. Data obtained over the last 5 years in several
laboratories have revitalized a controversial concept, namely the
autocrine feedback action of secreted insulin on L-cell function.
While, historically, insulin was suggested to exert a negative
e¡ect on L-cells, recent data provide evidence for a positive
role of insulin in transcription, translation, ion £ux, insulin se-
cretion and L-cell survival.
& 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
In adult mammals, L-cells of the pancreatic islets of Lan-
gerhans are the only source for the peptide hormone insulin
and therefore these cells are of vital importance in maintain-
ing blood glucose homeostasis. L-cells not only produce insu-
lin but secrete the hormone in amounts appropriate to the
blood glucose concentration in order to keep blood glucose
levels within narrow limits. Dysfunction of pancreatic L-cells
is a major cause of the development of so-called non-insulin-
dependent diabetes or type 2 diabetes mellitus, the most com-
mon metabolic disorder in man.
Multiple signals of di¡erent origin guarantee appropriate
L-cell function under both basal and glucose-stimulated con-
ditions. These signals include humoral factors (hormones, vi-
tamins, nutrients, ions, etc.), nerve stimulation, as well as
factors of intraislet cell^cell communication. Whereas the
paracrine e¡ects on L-cells of glucagon, secreted from pancre-
atic K-cells and stimulating insulin release, and of somatostat-
in, secreted from N-cells and inhibiting insulin release, are well
accepted (for review see [1]), the autocrine e¡ect of secreted
insulin on L-cell function was and still is a matter of debate.
Although the idea of an autocrine feedback by insulin is not
new and dates back to the 1940s [2], both conceptual disagree-
ment and di¡erent results in the respective experiments con-
tribute to this still ongoing controversy. With regard to the
conceptual disagreement, the major argument is that L-cells
are exposed to so much insulin that the respective signal trans-
duction pathways must be desensitized. Experimentally, with
regard to the e¡ect of insulin upon insulin secretion for exam-
ple, all possible outcomes like negative feedback [3^8], posi-
tive feedback [9^11], and no e¡ect at all [12^15] have been
reported. Moreover, while historically insulin was exclusively
discussed as a negative signal [2^7,16], recent data provide
evidence for a positive role of insulin in several cellular pro-
cesses that include the regulation of gene transcription [17^
23], translation [18,24^26], Ca2þ £ux [9^11,27,28], insulin se-
cretion [9^11] and the potential role of insulin action in L-cell
survival [29]. One of the major points discussed as a source for
controversial results and conceptual disagreement was the
question whether the observed insulin e¡ect upon L-cell func-
tion is a direct one or rather secondary, mediated by factors
of non-L-cell origin. This mainly concerned experiments on
whole animals and perfused pancreata, but also the ‘arti¢cial
di¡usion e¡ect’ in studies on isolated islets, i.e. insulin coming
from outside and thus going the wrong way, was discussed.
The aim of the present review is to summarize both histor-
ical and recent data on insulin feedback, here focusing on the
two most controversially discussed areas, i.e. insulin expres-
sion/content and insulin secretion.
2. Insulin signaling in L-cells ^ the components
The ¢rst step in the insulin signaling cascade is binding of
insulin to the insulin receptor (IR) [30]. However, because
pancreatic L-cells are surely exposed to insulin concentrations
that are higher than those in the periphery [31], insulin-like
growth factor (IGF)-I and IGF-II receptors, which have a
lower a⁄nity for insulin [32], cannot be excluded as targets
for insulin binding. That L-cells are targets for insulin was
shown already in the 1980s in conventional radioligand bind-
ing assays [33] as well as by quantitative electron microscopic
autoradiography [34]. The presence of IR and IGF receptors
in insulin-producing cell lines was reported in [35] and [36,37],
respectively. Although recent data show that all four insulin
receptor substrate proteins, i.e. IRS-1, -2, -3 and -4, are de-
tectable in pancreatic L-cells [38] and that downstream located
e¡ector proteins, such as phosphoinositide 3P-kinase (PI3 ki-
nase), PKB/Akt, p70s6k, PHAS-1 can be activated by glucose
or direct insulin stimulation [17,19,21,24], it was a major
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breakthrough when Rothenberg et al. [39] and Velloso et al.
[40] in 1995 reported that insulin, secreted upon glucose stim-
ulation, activated the L-cell IR and the downstream located
IRS and PI3 kinase. These studies provided evidence for an
autocrine feedback action of insulin at the molecular level but
did not yet resolve whether insulin is a negative, positive or
complex (negative and positive) signal in L-cell function.
3. Insulin and insulin biosynthesis, insulin content and L-cell
mass
To our knowledge the ¢rst note on a potential negative
feedback action of insulin regarded insulin biosynthesis/insu-
lin content. In 1941 Best and Haist [2] reported that daily
injection of rats with insulin led to a reduced pancreatic in-
sulin content. The e¡ect of administered insulin is in agree-
ment with later reports on chronic administration of insulin or
the e¡ect of transplanted insulinomas (see [16]), all suggesting
that insulin is a negative regulator of L-cell mass/insulin con-
tent. However, chronic administration of insulin is associated
with hypoglycemia, a condition resulting in reduced insulin
biosynthesis. To circumvent this problem, Koranyi et al. [16]
combined hyperinsulinemic clamps with glucose clamps.
Again, this study employing a 12-h insulin infusion at ¢xed
glucose levels suggested a negative e¡ect on insulin biosynthe-
sis but did not reveal whether the insulin e¡ect was a direct
one. In contrast to these studies, disruption of insulin signal-
ing in animal models at the level of IRS-2, as in the IRS-2
knockout mouse [41], or in the L-cell restricted knockout of
the IR, LIRKO mouse [42], led to the reduction in pancreatic
insulin content in the adult state and consequently to the
development of a type 2 diabetes mellitus-like phenotype.
Although a genetically engineered knockout of insulin expres-
sion led to L-cell hyperplasia in the prenatal state [43], thus
supporting the idea of insulin being a negative regulator in
maintaining L-cell mass, surprisingly neither the L-cell re-
stricted knockout of the IR [42] or the IGF-IR (LIGFIRKO)
[44], nor the combined general knockout of IR and IGF-IR
[45] led to a change in L-cell mass prenatally, suggesting that
neither insulin nor IGF-I seems to be involved in L-cell pro-
liferation. In contrast to the LIGFIRKO mouse, LIRKO mice
show an age-dependent decrease in L-cell mass which indicates
a di¡erent function of the two receptors in the postnatal de-
velopment of islets. However, a note of caution is necessary.
Because all L-cell restricted knockouts are based on the ex-
pression of Cre recombinase under control of the insulin pro-
moter, the possibility of the importance of the knocked-out
component before the time of insulin expression (day 13 of
embryogenesis [46]), thus Cre expression and generation of the
knockout, cannot be ruled out.
While historically the reduction in insulin biosynthesis was
the ¢rst suggestion for a possible negative feedback action of
insulin [2], the increase in insulin biosynthesis was the ¢rst
suggestion for a positive feedback action of the hormone
[17,18]. While our data revealed that insulin, secreted upon
glucose stimulation, is a key factor in glucose-dependent up-
regulation of insulin gene transcription in primary rat and
mouse L-cells as well as in the insulin-producing cell line
HIT-T15 by signaling through IR-A/PI3 kinase/p70s6k [17],
Xu and Rothenberg [18] at the same time reported that over-
expression of IR in the insulin-producing cell line LTC6 led to
an increase in insulin mRNA levels, insulin content and in-
sulin secretion. Further data showed that insulin stimulates
protein biosynthesis in insulin-producing cells in general
[24,25] as well as insulin biosynthesis itself [18,25].
Of the mechanisms that are associated with insulin-depen-
dent insulin biosynthesis, the best studied are those involved
in the insulin-dependent stimulation of insulin gene transcrip-
tion. Since in the process of insulin secretion the concentra-
tion of the hormone reaches levels much higher than observed
in peripheral blood, an interesting question was whether in-
sulin activates the transcription of its own gene by signaling
through the IR or through IGF-IR. Stimulation with IGF-I
did not activate insulin promoter activity nor did blocking of
IGF-I receptors, using speci¢c blocking antibodies, abolish
insulin-stimulated up-regulation of insulin promoter activity
[21]. On the other hand, overexpression of IRs led to a pro-
nounced activation of the insulin promoter in response to
either glucose or insulin, whereas blocking IRs by employing
IR-blocking antibodies drastically reduced up-regulation of
insulin promoter activity by the two stimuli [21]. The most
convincing evidence for the involvement of IRs in this signal-
ing cascade came from experiments in islets isolated from
LIRKO mice [42]. Exposure of these islets to either elevated
glucose concentration or exogenous insulin did not result in
the up-regulation of endogenous insulin gene transcription as
was the case in islets prepared from control animals [21].
The IR exists in two isoforms as a result of alternative
splicing of the 11th exon (for review see [47]). The A-type
(IR-A, Ex113) lacks the 12 amino acids encoded by exon
11, whereas the B-type (IR-B, Ex11+) contains the respective
amino acid sequence, which is located extracellularly at the C-
terminus of the K-subunit of the receptor. Pancreatic L-cells as
well as insulin-producing cell lines express both isoforms in an
almost one-to-one ratio (own unpublished data). Overexpres-
sion of IR-A led to a pronounced e¡ect of insulin stimulation
on insulin promoter activation, while overexpression of IR-B
did not [17,21]. More interestingly, selective blocking of B-
type receptor signaling, using a blocking antibody raised
against the 12 amino acids encoded by exon 11, abolished
insulin-stimulated up-regulation of the glucokinase promoter
but had no e¡ect on insulin-stimulated up-regulation of the
insulin promoter in the same cell [21]. This led us to suggest
that insulin activates the transcription of its own gene by
signaling through the A-type rather than through the B-type
insulin receptor.
A general consensus exists on the involvement of PI3 kinase
in glucose/insulin-dependent up-regulation of insulin gene
transcription [17,19^21]. Inhibition of PI3 kinase by the phar-
macological inhibitors wortmannin and LY294002 abolishes
glucose- as well as insulin-induced up-regulation of insulin
gene transcription [17,19^21]. The tested dose response of
wortmannin and LY294002 and the e¡ect of the dominant-
negative acting mutant of the PI3 kinase class Ia adapter
protein p85, i.e. vp85, led to the conclusion that members
of the PI3 kinase class Ia participate in the signal transduc-
tion. The downstream targets of PI3 kinase Ia are, however,
less clear. Our own data favor the involvement of p70s6k in
glucose/insulin-dependent up-regulation of insulin gene tran-
scription. This is based on the ¢nding that overexpression of
a rapamycin-insensitive mutant of p70s6k, i.e. p70v2^46/
vCT104 [48], combined with rapamycin treatment and glu-
cose/insulin stimulation of L-cells led to levels of insulin pro-
moter activation that were similar to those obtained following
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stimulation of mock-transfected cells in the absence of rapa-
mycin [17].
In agreement with the discussion of PDX-1 being one of the
transcription factors involved in glucose-stimulated up-regu-
lation of insulin gene transcription, Wu et al. [20] reported
increased binding of PDX-1 to its binding sites in the insulin
promoter in response to insulin.
4. Insulin and insulin secretion
The concept that insulin a¡ects its own secretion is not new,
however, the area is still controversial and currently under
discussion. Historically, insulin secretion was suggested to be
inhibited by secreted insulin [3^7], but on the other hand,
similar models used by others fail to support this concept
[12^14]. Most interestingly, recent data suggest that secreted
insulin may have a positive e¡ect on insulin exocytosis [9^
11,27,28,42]. Aspinwall and co-workers [9] reported that se-
creted insulin stimulates the immediate, ongoing process of
insulin exocytosis, very likely due to an insulin-dependent in-
crease in cytosolic free Ca2þ ([Ca2þ]i) [9,10].
The hypothesis that insulin signaling contributes to insulin
secretion is supported by the analysis of two animal models.
The LIRKO mouse, having a L-cell restricted knockout of the
IR, exhibits a selective loss of glucose-stimulated acute insulin
secretion and develops a diabetes type 2-like phenotype at the
age of 8 weeks [42]. A similar phenotype is shown by the
LIGFIRKO mouse with a L-cell restricted knockout of the
IGF-1R [44]. Since the non-altered secretory response towards
arginine stimulation demonstrated no failure at the level of
the exocytotic machinery, the phenotype rather seems to be
caused by a defect at the level of glucose sensing/metabolism
and/or Ca2þ handling. However, care must be taken in linking
the longer-term knockout e¡ect(s) with the acute regulation
demonstrated in the biochemical experiments discussed below.
As mentioned above, in some reports, feedback via the IR
has been suggested to be part of a feed-forward mechanism
that stimulates insulin secretion by increasing [Ca2þ]i [9^
11,27,28]. Aspinwall and co-workers [9,10] show an insulin-
stimulated increase in [Ca2þ]i within seconds after the start of
stimulation, which originates from intracellular Ca2þ stores
rather than from extracellular Ca2þ entry and involves IRS-
1 and PI3 kinase activity. Similar dynamics with regard to
increases in [Ca2þ]i and insulin release were observed by Ro-
per et al. [11] when using the fungal insulin mimetic L-
783,281, again via an IRS-1/PI3 kinase-dependent pathway.
Data from Wolf’s laboratory also identify IRS-1 as a key
regulator in insulin-dependent L-cell Ca2þ homeostasis but
suggest a di¡erent mechanism. The key di¡erences in these
studies are whether the rise in [Ca2þ]i is dependent on PI3
kinase [9^11] or not [27,28] as well as the source of the
[Ca2þ]i rise, i.e. blockade of the endoplasmic reticulum
Ca2þ-ATPase SERCA [27,28] or a more direct mobilization
of Ca2þ from the endoplasmic reticulum [10,11]. These con-
troversies, however, may be explained by the di¡erent exper-
imental set-up. While in [9^11] only a 30-s insulin stimulus
had been used, the data described in [27,28] were obtained
after a 72-h exposure to elevated insulin.
A possible mechanism for the positive involvement of in-
sulin signaling at the level of glucose sensing/metabolism is the
insulin-dependent regulation of the ‘glucose sensor’ glucoki-
nase. Data in support of this model show that glucose-depen-
dent transcription of the glucokinase gene in pancreatic L-cells
requires insulin signaling via IR-B/PI3 kinase class IIK-like
activity and very likely PKB/Akt [21]. More interestingly, Riz-
zo et al. [49] recently reported that the recruitment of active
glucokinase molecules from the inactive pool is insulin-depen-
dent. Because of the slow kinetics of the insulin-dependent
recruitment of activated glucokinase molecules, i.e. several
minutes, this particular mechanism is unlikely to be involved
in the immediate e¡ect of insulin on the ¢rst phase of secre-
tion as reported in [9^11], which takes place within seconds
after exocytosis. However, the long-term e¡ect of the lack of
insulin-dependent regulation of glucokinase protein expres-
sion and enzyme activation may partly explain the abolished
glucose-dependent ¢rst-phase secretory response observed in
the LIRKO and LIGFIRKO mouse models [42,44].
Noteworthy, also the recent observations do not settle the
old dispute. Besides the reported positive e¡ect of insulin on
insulin secretion there are new arguments in support of an
immediate negative feedback [5,8]. These latter studies show
that a further possible mechanism for insulin to regulate its
secretion is to modulate the activity of the KATP channel. In
neurons it has been suggested that stimulation by insulin via
the activation of PI3 kinase and the production of phospha-
tidylinositol 3,4,5-trisphosphate (PI(3,4,5)P3) can serve to
open the KATP channel [50]. If this were to occur in the L-
cell, the stimulus^secretion coupling should be switched o¡. In
parallel work on a rat insulinoma L-cell model (GRI-G1), the
same group was unable to see similar e¡ects on the KATP
channel although PI(3,4,5)P3 levels were signi¢cantly in-
creased [51]. However, a recent study on a more physiologi-
cally relevant model, normal mouse L-cells, has produced evi-
dence that KATP channels can be opened by insulin via PI3
kinase [5], the most likely candidate being PI(3,4,5)P3. Both
phosphatidylinositol 4,5-bisphosphate and PI(3,4,5)P3 have
been suggested to be physiological ‘openers’ of KATP chan-
nels, thereby shifting the ATP-dependent closure of the chan-
nel into the physiological range of ATP concentrations [52].
The aforementioned studies of normal mouse L-cells have
demonstrated a PI3 kinase-dependent inactivation of insulin
secretion by hyperpolarization of the plasma membrane [5],
the latter providing the potential molecular basis for pulsatile
insulin release [53] via the probable production of PI(3,4,5)P3.
Moreover, there are data showing an increased glucose-
stimulated insulin release after inhibition of PI3 kinase or in
islets of p853=3 mice [6,15,54,55], indeed suggesting that in-
sulin has a negative e¡ect on L-cell stimulus^secretion cou-
pling. Interestingly, Eto et al. [54] report that inhibition of
PI3 kinase did not interfere with the secretion-triggered path-
way including glucose oxidation, ATP content or [Ca2þ]i, but
suggest the e¡ect to be distal to the increase in [Ca2þ]i. It is
noteworthy, however, that in the mentioned reports the inhi-
bition of PI3 kinase led to an increase only in the second
phase of insulin release. Finally, recent data by Zawalich
and Zawalich [15] suggest that perifusion of isolated rat islets
for 45 min with exogenous insulin has neither a positive nor a
negative e¡ect on endogenous insulin secretion.
5. Concluding remarks
The aim of this review was to summarize old and new data
of insulin feedback action on L-cell function with special em-
phasis on insulin biosynthesis/content and insulin secretion
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(see Table 1). Whereas historically insulin was discussed as a
negative signal [3^7] or having no e¡ect [12^14] on L-cell
function, recent data provide evidence for a positive role of
insulin in several cellular processes that include the regulation
of gene transcription [17^23], translation [18,24^26], Ca2þ £ux
[9^11,27,28], insulin secretion [9^11,27,28] and the potential
role of insulin action in L-cell survival [29]. Interestingly,
also the recent data do not settle the old dispute but instead
provide further contradictory results on insulin biosynthesis
[18,25,56] and exocytosis [5,8^11,15].
However, as contradictory as these reports might look at
¢rst glance, perhaps the di¡erent experimental conditions used
may o¡er the explanation for the reported results. One crucial
aspect may be the dynamics of events triggered by insulin. In
fact, secreted insulin activates its own receptor and thereby
PI3 kinase rapidly. This may indeed form the basis for an
immediate, i.e. within seconds to a few minutes, in£uence
on even the ¢rst phase of insulin exocytosis, as reported in
[5,8^11], very likely mediated by IRS and/or PI3 kinase prod-
ucts. The next level of insulin action may regulate processes
within several minutes, such as gene transcription [17,19^
21,23], and translation [24^26]. These processes will involve
the activation of signal transduction downstream of PI3 ki-
nase and thus trigger protein phosphorylation/dephosphoryla-
tion, protein translocation, protein^protein interaction and
protein^DNA interaction, but will not require the synthesis
of new proteins. This level of insulin action may also include
the modulation of the ¢rst as well as the second phase of
insulin secretion, the latter by promoting recruitment of secre-
tory granules to the plasma membrane. Longer-term e¡ects of
insulin feedback action, i.e. after 30 min, may be achieved by
the synthesis of proteins, including transcription factors, that
regulate expression of further genes. Moreover, insulin action
may trigger the sequential activation of positive/activating and
negative/inactivating signals. This may involve the sequential
activation of tyrosine kinases/phosphatases and serine/threo-
nine kinases/phosphatases, similar to the sequence of events
that leads to the activation (i.e. tyrosine phosphorylation by
the IR) and later inactivation (i.e. serine phosphorylation by
insulin-activated atypical protein kinase C) of IR and IRS
[57].
Another explanation for the controversy in results may
come from the mode of exposure of L-cells to insulin. In
physiology, i.e. under basal as well as stimulated conditions,
pancreatic L-cells secrete insulin in a pulsatile manner [53].
The physiological signi¢cance of this oscillatory insulin release
has been discussed in the context of it being a more e¡ective
signal for peripheral target tissues. However, perhaps even
more important, this pulsatile insulin release may be the guar-
antee that pancreatic L-cells are responsive to insulin at all.
Continuous exposure of L-cells to high levels of insulin, as is
the case in insulin clamp studies or as a result of long-term
incubation of L-cells with insulin secretagogues, may indeed
result in a negative feedback or even in a lack of response, due
to the desensitization of the signaling cascade. Interestingly,
loss of pulsatile insulin release is already observed in the early
stages of type 2 diabetes [53].
Taken together, a growing body of evidence demonstrates
Table 1
E¡ect of insulin on L-cell function
Biological function E¡ect Cell or tissue type Signaling Reference
Transcription
insulin gene down-regulation rat islets ? [1]
insulin gene no e¡ect rat islets [56]
insulin gene up-regulation HIT, islets (rat, ob mouse) IR-A/PI3K-Ia/p70s6k [17,21,22]
insulin gene up-regulation MIN6 PI3K-Ia [19]
insulin gene up-regulation MIN6, human islets PDX1-binding [20]
insulin gene up-regulation LTC6-F7/IR ? [18]
glucokinase gene up-regulation HIT, islet (rat, ob mouse) IR-B/PI3K-II/PDK1/PKB [21,22]
acetyl-CoA carboxylase gene up-regulation MIN6 SREBP1c [23]
Translation
general up-regulation RINm5F, rat islets PHAS-1 [24]
general, insulin up-regulation rat islets ? [25]
general, insulin up-regulation LTC6-F7/IR ? [18]
IA-2 up-regulation rat and human islets ? [26]
Insulin content negative various models ? [2,16] and references in [16]
positive LTC6-F7/IR ? [18]
positive IRS2 KO mouse IRS2 [41]
positive LIRKO mouse [42]
Insulin secretion negative various models ? [3^7]
no e¡ect various models [12^14]
positive mouse islets, IRS3=3 cells PI3K/IRS1, SERCA? [10,11]
positive LTC6-F7/IR, rat islets IRS1, SERCA [27,28]
negative mouse islets PI3K [5]
negative human islets PI3K [8]
no e¡ect rat islets [15]
positive LIRKO mouse ? [42]
negative p853=3 mouse islets PI3K Ia [54]
Cytosolic free Ca2þ increase mouse islets, IRS3=3 cells PI3K/IRS1, SERCA? [10,11]
increase LTC6-F7/IR, rat islets IRS1, SERCA [27,28]
Proliferation negative insulin KO mouse [43]
no e¡ect LIRKO mouse [42]
no e¡ect LIGFIRKO mouse [44]
no e¡ect IR-IGF1R KO mouse [45]
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that autocrine insulin feedback, resulting in both positive and
negative e¡ects, is involved in regulating proper L-cell func-
tion. However, it has to be stressed that under normal, phys-
iological conditions insulin feedback takes place at a time
when the pancreatic L-cells face a multiple input of signals
that accompany food intake and digestion. This includes neu-
ral factors, the action of incretines, enforced intraislet cell^cell
communication, elevated glucose metabolism and elevated
Ca2þ levels in L-cells, and last but not least the potential feed-
back action of factors co-secreted with insulin. All these fac-
tors will, in addition to providing the basis for a complex
cross-talk between various signaling pathways in pancreatic
L-cell function, also a¡ect insulin-induced signal transduction.
Future research will not only have to clarify which process-
es that have previously been described to be neural/incretine/
paracrine/glucose-dependent, are in fact insulin-dependent,
but will also have to show to what extent maintenance of L-
cell function is dependent on the autocrine insulin feedback
action. Thus, impairment of insulin signaling in L-cells as
proposed in the ‘L-cell insulin resistance’ concept will lead
to and/or accelerate dysfunction of the L-cell, as seen in
type 2 diabetes.
Acknowledgements: Cited work from the authors of this review was
¢nancially supported by grants from the Karolinska Institutet, the
Swedish Research Council (72X-12594, 03X-13394, 31X-14303), the
Swedish Diabetes Association, the National Institutes of Health
(DK58508), Juvenile Diabetes Research Foundation, Berth von Kant-
zows Foundation, Novo Nordisk Foundation.
References
[1] Pipeleers, D., Kiekens, R. and In’t Veld, P. (1992) in: Insulin.
Molecular Biology to Pathology (Ashcroft, F.M. and Ashcroft,
S.J.H., Eds.), pp. 5^31, IRL Press, Oxford.
[2] Best, C.H. and Haist, R.E. (1941) J. Physiol. 100, 142^146.
[3] Iversen, J. and Miles, D.W. (1971) Diabetes 20, 1^9.
[4] Elahi, D., Nagulesparan, M., Hershcopf, R.J., Muller, D.C., To-
bin, J.D., Blix, P.M., Rubenstein, A.H., Unger, R.H. and An-
dres, R. (1982) New Engl. J. Med. 306, 1196^1202.
[5] Khan, F.A., Goforth, P.B., Zhang, M. and Satin, L.S. (2001)
Diabetes 50, 2192^2198.
[6] Zawalich, W.S. and Zawalich, K.C. (2000) Endocrinology 141,
3287^3295.
[7] Zawalich, W.S., Tesz, G.J. and Zawalich, K.C. (2001) J. Biol.
Chem. 276, 37120^37123.
[8] Persaud, S.J., Asare-Anane, H. and Jones, P.M. (2002) FEBS
Lett. 510, 225^228.
[9] Aspinwall, C.A., Lakey, J.R.T. and Kennedy, R.T. (1999) J. Biol.
Chem. 274, 6360^6365.
[10] Aspinwall, C.A., Qian, W.J., Roper, M.G., Kulkarni, R.N.,
Kahn, C.R. and Kennedy, R.T. (2000) J. Biol. Chem. 275,
22331^22338.
[11] Roper, M.G., Qian, W., Zhang, B.B., Kulkarni, R.N., Kahn,
C.R. and Kennedy, R.T. (2002) Diabetes 51 (Suppl. 1), S43^
S49.
[12] Malaisse, W.J., Malaisse-Lagae, F., Lacy, P.E. and Wright, P.H.
(1967) Proc. Soc. Exp. Biol. Med. 124, 497^500.
[13] Schatz, H. and Pfei¡er, E.F. (1977) J. Endocrinol. 74, 243^
249.
[14] Stagner, J., Samols, E., Polonsky, K. and Pugh, W. (1986) J. Clin.
Invest. 78, 1193^1198.
[15] Zawalich, W.S. and Zawalich, K.C. (2002) J. Biol. Chem. 277,
26233^26237.
[16] Koranyi, L., James, D.E., Kraegen, E.W. and Permutt, M.A.
(1992) J. Clin. Invest. 89, 432^436.
[17] Leibiger, I.B., Leibiger, B., Moede, T. and Berggren, P.O. (1998)
Mol. Cell 1, 933^938.
[18] Xu, G.G. and Rothenberg, P.L. (1998) Diabetes 47, 1243^1252.
[19] Da Silva Xavier, G., Varadi, A., Ainscow, W.K. and Rutter,
G.A. (2000) J. Biol. Chem. 275, 36269^36277.
[20] Wu, H., Macfarlane, W.M., Tadayyon, M., Arch, J.R.S., James,
R.F.L. and Docherty, K. (1999) Biochem. J. 344, 813^818.
[21] Leibiger, B., Leibiger, I.B., Moede, T., Kemper, S., Kulkarni,
R.N., Kahn, C.R., de Vagas, L.M. and Berggren, P.O. (2001)
Mol. Cell 7, 559^570.
[22] Leibiger, B., Moede, T., Uhles, S., Berggren, P.O. and Leibiger,
I.B. (2002) Biochem. Soc. Trans. 30, 312^317.
[23] Andreolas, C., da Silva Xavier, G., Diraison, F., Zhao, C., Var-
adi, A., Lopez-Casillas, F., Ferre, P., Foufelle, F. and Rutter,
G.A. (2002) Diabetes 51, 2536^2545.
[24] Xu, G., Kwon, G., Marshall, C.A., Lin, T.A., Lawrence Jr.,
J.C. and McDaniel, M.L. (1998) J. Biol. Chem. 273, 28178^
28184.
[25] Leibiger, B., Waﬁhlander, K., Berggren, P.O. and Leibiger, I.B.
(2000) J. Biol. Chem. 275, 30153^30156.
[26] Lo«bner, K., Steinbrenner, H., Roberts, G.A., Ling, Z., Huang,
G.-C., Piquer, S., Pipeleers, D.G., Seissler, J. and Christie, M.R.
(2002) Diabetes 51, 2982^2988.
[27] Xu, G.G., Gao, Z.Y., Borge Jr., P.D. and Wolf, B.A. (1999)
J. Biol. Chem. 274, 18067^18074.
[28] Xu, G., Gao, Z., Borge Jr., P.D., Jegier, P.A., Young, R.A. and
Wolf, B.A. (2000) Biochemistry 39, 14912^14919.
[29] Kwon, G., Xu, G., Marshall, C.A. and McDaniel, M.L. (1999)
J. Biol. Chem. 274, 18702^18707.
[30] White, M.F. and Kahn, C.R. (1994) J. Biol. Chem. 269, 1^
4.
[31] Zawalich, W.S., Karl, R.C., Ferrendelli, J.A. and Matschinsky,
F.M. (1975) Diabetologia 11, 231^235.
[32] Yarden, Y. and Ullrich, A. (1988) Annu. Rev. Biochem. 57, 443^
478.
[33] Verspohl, E.J. and Ammon, H.P.T. (1980) J. Clin. Invest. 65,
1230^1237.
[34] Patel, Y.C., Amherdt, M. and Orci, L. (1982) Science 217, 1155^
1156.
[35] Gozzano, H., Halban, P., Prentki, M., Ballotti, R., Brandenburg,
D., Fehlmann, M. and van Obbergen, E. (1985) Biochem. J. 226,
867^872.
[36] Van Schravendijk, C.F.H., Foriers, A., van den Brande, J. and
Pipeleers, D.G. (1987) Endocrinology 121, 1784^1788.
[37] Katz, L.E.L., Bhala, A., Camron, E., Nunn, S.E., Hintz, R.L.
and Cohen, P. (1997) J. Endocrinol. 152, 455^464.
[38] Kulkarni, R.N., Winnay, J.N., Daniels, M., Bruning, J.C., Flier,
S.N., Hanahan, D. and Kahn, C.R. (1999) J. Clin. Invest. 104,
R69^R75.
[39] Rothenberg, P.L., Willison, L.D., Simon, J. and Wolf, B.A.
(1995) Diabetes 44, 802^809.
[40] Velloso, L.A., Carneiro, E.M., Crepaldi, S.C., Boschero, A.C.
and Saad, M.J.A. (1995) FEBS Lett. 377, 353^357.
[41] Withers, D.J., Gutierrez, J.S., Towery, H., Burks, D.J., Ren,
J.M., Previs, S., Zhang, Y., Bernal, D., Pons, S., Shulman,
G.I., Bonner-Weir, S. and White, M.F. (1998) Nature 391,
900^904.
[42] Kulkarni, R.N., Bruning, J.C., Winnay, J.N., Postic, C., Magnu-
son, M.A. and Kahn, C.R. (1999) Cell 96, 329^339.
[43] Duville, B., Currie, C., Chrones, T., Bucchini, D., Jami, J., Joshi,
R.L. and Hill, D.J. (2002) Endocrinology 143, 153^157.
[44] Kulkarni, R.N., Holzenberger, M., Shih, D.Q., Ozcan, U., Stof-
fel, M., Magnuson, M.A. and Kahn, C.R. (2002) Nature Genet.
31, 111^115.
[45] Kido, Y., Nakae, J., Hribal, M.L., Xuan, S., Efstradiadis, A. and
Accili, D. (2002) J. Biol. Chem. 277, 36740^36747
[46] Gannon, M., Shiota, C., Postic, C., Wright, C.V.E. and Magnu-
son, M.A. (2000) Genesis 26, 139^141.
[47] Flier, J.S. (1996) in: Diabetes Mellitus (LeRoith, D., Tailor, S.I.
and Olefsky, J.M., Eds.), pp. 148^154, Lippincott-Raven, Phila-
delphia, PA.
[48] Weng, Q.-P., Andrabi, K., Kozlowski, M.T., Grove, J.R. and
Avruch, J. (1995) Mol. Cell. Biol. 15, 2333^2340.
[49] Rizzo, M.A., Magnuson, M.A., Drain, P.F. and Piston, D.W.
(2002) J. Biol. Chem. 277, 34168^34175.
[50] Spanswick, D., Smith, M.A., Mirshamsi, S., Routh, V.H. and
Ashford, M.L. (2000) Nature Neurosci. 8, 757^758.
[51] Harvey, J., McKay, N.G., Walker, K.S., Van der Kaay, J.,
FEBS 26747 19-11-02
I.B. Leibiger et al./FEBS Letters 532 (2002) 1^6 5
Downes, C.P. and Ashford, M.L. (2000) J. Biol. Chem. 275,
4660^4669.
[52] Larsson, O., Barker, C.J. and Berggren, P.O. (2000) Diabetes 49,
1409^1412.
[53] Porksen, N. (2002) Diabetologia 45, 3^20.
[54] Eto, K., Yamashita, T., Tsubamoto, Y., Terauchi, Y., Hirose,
K., Kubota, N., Yamashita, S., Taka, J., Satoh, S., Sekihara, H.,
Tobe, K., Iino, M., Kimura, S. and Kadowaki, T. (2002) Dia-
betes 51, 87^97.
[55] Jonas, J.C., Plant, T.D., Gilon, P., Detimary, P., Nenquin, M.
and Henquin, J.C. (1995) Br. J. Pharmacol. 114, 872^880.
[56] Tilmar, L., Carlsson, C. and Welsh, N. (2002) J. Biol. Chem. 277,
1099^1106.
[57] Kellerer, M. and Haring, H.U. (1995) Diabetes Res. Clin. Pract.
28 (Suppl.), 173^177.
FEBS 26747 19-11-02
I.B. Leibiger et al./FEBS Letters 532 (2002) 1^66
